Genfit S.A. ADR (GNFT)

May 22, 2025, 4:10 PM EDT - 14 days ago

GENFIT Reports First Quarter 2025 Financial Information

May 20, 2025, 4:10 PM EDT - 16 days ago

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy

May 14, 2025, 4:10 PM EDT - 22 days ago

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

May 7, 2025, 4:10 PM EDT - 4 weeks ago

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

May 5, 2025, 1:30 AM EDT - 4 weeks ago

GENFIT to Present Latest ACLF Research at EASL Congress 2025

Apr 29, 2025, 3:10 PM EDT - 5 weeks ago

GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F

Apr 28, 2025, 4:10 PM EDT - 5 weeks ago

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

Apr 24, 2025, 4:10 PM EDT - 6 weeks ago

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

Apr 10, 2025, 6:56 AM EDT - 2 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

CAMP EWTX

Mar 20, 2025, 5:10 PM EDT - 2 months ago

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

Mar 10, 2025, 5:10 PM EDT - 3 months ago

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

Feb 27, 2025, 4:10 PM EST - 3 months ago

GENFIT Announces Revenues and Cash Position as of December 31, 2024

Feb 21, 2025, 2:30 AM EST - 3 months ago

GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting

Feb 14, 2025, 4:10 PM EST - 3 months ago

GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders

Feb 6, 2025, 4:10 PM EST - 4 months ago

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

Jan 30, 2025, 2:40 AM EST - 4 months ago

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

Jan 29, 2025, 4:10 PM EST - 4 months ago

GENFIT Announces 2025 Financial Calendar

Jan 13, 2025, 4:10 PM EST - 5 months ago

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Nov 13, 2024, 4:10 PM EST - 7 months ago

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

Nov 7, 2024, 4:10 PM EST - 7 months ago

GENFIT Reports Third Quarter 2024 Financial Information

Sep 24, 2024, 8:51 AM EDT - 9 months ago

Top 4 Health Care Stocks That May Keep You Up At Night

BFRG DOCS GILD

Sep 23, 2024, 1:30 AM EDT - 9 months ago

GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

Jul 26, 2024, 7:45 AM EDT - 11 months ago

GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis

Jun 17, 2024, 4:10 PM EDT - 1 year ago

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

Jun 10, 2024, 5:22 PM EDT - 1 year ago

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis

Jun 10, 2024, 5:08 PM EDT - 1 year ago

US FDA approves Genfit and Ipsen's liver disease drug

May 29, 2024, 4:10 PM EDT - 1 year ago

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

May 29, 2024, 1:52 PM EDT - 1 year ago

Genfit: Under The Radar Biotech With Upcoming Catalysts

May 22, 2024, 12:05 PM EDT - 1 year ago

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

May 14, 2024, 4:10 PM EDT - 1 year ago

GENFIT Reports First Quarter 2024 Financial Information

Apr 25, 2024, 4:10 PM EDT - 1 year ago

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

Apr 15, 2024, 4:10 PM EDT - 1 year ago

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

Apr 5, 2024, 2:00 PM EDT - 1 year ago

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

Apr 4, 2024, 4:10 PM EDT - 1 year ago

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 4:10 PM EST - 1 year ago

GENFIT Announces Revenues and Cash Position as of December 31, 2023

Jan 15, 2024, 4:10 PM EST - 1 year ago

GENFIT Announces 2024 Financial Calendar

Dec 8, 2023, 1:55 AM EST - 1 year ago

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

Dec 6, 2023, 11:30 AM EST - 1 year ago

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

Nov 27, 2023, 7:30 AM EST - 1 year ago

Genfit: Large PBC Market, Liquidity To Await Approval

Nov 16, 2023, 4:10 PM EST - 1 year ago

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Nov 13, 2023, 4:30 PM EST - 1 year ago

GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

Nov 9, 2023, 4:10 PM EST - 1 year ago

GENFIT Reports Third Quarter 2023 Financial Information

Nov 2, 2023, 5:10 PM EDT - 1 year ago

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

Sep 26, 2023, 4:10 PM EDT - 1 year ago

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

Sep 5, 2023, 4:10 PM EDT - 1 year ago

GENFIT to Participate in Upcoming Investor Conferences

Aug 10, 2023, 4:10 PM EDT - 1 year ago

GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

Jun 30, 2023, 6:56 AM EDT - 2 years ago

These strategists say investors need quality, so sell Tesla and AMD, and buy these stocks instead.

AAPL NKE

Jun 30, 2023, 6:44 AM EDT - 2 years ago

U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease

Jun 30, 2023, 1:00 AM EDT - 2 years ago

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Jun 30, 2023, 1:00 AM EDT - 2 years ago

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease